AnaptysBio (ANAB) investors back director slate, auditor and equity plan changes
Rhea-AI Filing Summary
AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders on August 11, 2026 and reported the results of four proposals. Two Class III directors, Hollings Renton and John P. Schmid, were elected to three-year terms expiring at the 2029 annual meeting. Renton received 15,304,522 shares for and 6,613,642 withheld/abstaining votes, while Schmid received 20,314,669 shares for and 1,603,495 withheld/abstaining votes; each proposal had 2,084,465 broker non-votes. Stockholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2027, with 22,343,352 shares for and 1,640,401 against. They also gave non-binding advisory approval to named executive officer compensation with 21,274,791 shares for and approved an amendment to the 2017 Equity Incentive Plan with 15,563,882 shares for.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
broker non-votes financial
non-binding, advisory approval financial
independent registered public accounting firm financial
Equity Incentive Plan financial
FAQ
What did AnaptysBio (ANAB) stockholders decide at the 2026 annual meeting?
How did AnaptysBio (ANAB) vote on its Class III director nominees in 2026?
Was KPMG LLP ratified as AnaptysBio (ANAB) auditor for fiscal 2027?
How did AnaptysBio (ANAB) stockholders vote on executive compensation in 2026?
What happened with AnaptysBio’s (ANAB) 2017 Equity Incentive Plan at the 2026 meeting?
Which proposals at AnaptysBio’s (ANAB) 2026 meeting had broker non-votes?
AI-generated analysis. How Rhea-AI works. Not financial advice.